MicroPort® Participates in Arab Health 2024, Completing the World’s First Cross-Border 5G Simulated Tele-Surgery Verification

Dubai, UAE, 28 February, 2024 – From 29 January to 1 February, the 49th edition of Arab Health took place in Dubai. This year, Arab Health, one of the world’s largest comprehensive medical device and equipment exhibitions, attracted over 130,000 healthcare professionals from more than 190 countries and regions. MicroPort® and its associated companies participated in the exhibition, showcasing a range of innovative products and solutions in areas such as Coronary Intervention, Structural Heart Disease, Electrophysiology, Surgical Robotics, Extracorporeal Life Support, Urology, Endocrinology, and more.

A highlight of this event was the Toumai® laparoscopic surgical robot (Toumai®) developed by MicroPort® MedBot. This surgical robot achieved a groundbreaking feat by successfully completing the world’s first ultra-remote cross-border 5G simulated tele-surgery verification, spanning nearly 7,000 kilometers. During the tele-surgery, the staff controlled Toumai®’s patient cart at the Dubai booth through the surgeon console in Shanghai, performing precise and smooth surgical operations such as dissection, traction, clamping, cutting, and suturing.

Despite the nearly 7,000 kilometers of distance and relying solely on a 5G SIM card, there were no signal interruptions or operational delays during the surgery. Various surgical actions were executed with near synchrony, completed by clear and well-coordinated communication. The entire process showcased clear visibility, stable operation of the robotic arm, and flexible maneuverability of the instrument, with clipping and suturing performances comparable to local operations. The impressive performance of Toumai® drew numerous medical experts to assess the robot. They expressed positive interest in its current application in 5G tele-surgery and inquired about its previous clinical performance.

Throughout the event, MicroPort® displayed a diverse range of products across pan-vascular, pan-surgical, and emerging medical fields. Among the showcased products were MicroPort® Coronary’s Rapamycin Target Eluting Coronary Stent System and PTCA Balloon Dilatation Catheter, which have already reached 56 countries and regions. The showcase also included the VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System, the latest generation Columbus 3D EP Navigation System, the FireMagic TrueForce Ablation Catheter, the VitaSprings® Spiral Diversion Integrated Membrane Oxygenator, the MOBYBOX System, and other innovative products. These products, making strong strides in global markets, are anticipated to become commercially available in the Middle East and other regions in the near future.

Jonathan Chen, Chief International Business Officer of MicroPort®, stated that, "This exhibition is a fantastic platform for showcasing MicroPort®'s diverse product line and powerful comprehensive medical innovation technology to a global audience. We engaged in meaningful discussions on cooperation with partners and leading medical institutions worldwide, establishing a solid foundation for future innovative collaborations. Furthermore, representatives from all MicroPort® business units held discussions on cooperation and commercialization plans with over 250 potential customers and partners from various countries, including Morocco, India, Sri Lanka, and Saudi Arabia. MicroPort® is committed to further enhancing our global strategic plan for the long term. By leveraging the 'One MicroPort®' platform, we aim to maximize resource utilization, foster close collaborations with medical professionals globally, and dedicate ourselves to providing high-quality and comprehensive solutions to patients worldwide."

About MicroPort®

Founded in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) is a global medical devices company. MicroPort® provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, cardiac rhythm management, electrophysiology, endovascular, neurovascular and surgical robotics among others. For over 25 years, MicroPort® has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can continue living better and longer lives. With therapeutic solutions that are available in more than 100 countries and over 20,000 hospitals around the world, today, every 5 seconds a patient around the world benefits from a MicroPort® life-changing solution.

More information is available at www.microport.com.